SAN JOSE, California and Woodcliff Lake, New Jersey, January 28, 2020 - BioPharmX Corporation (NYSE American: BPMX) ("BioPharmX") and Timber Pharmaceuticals LLC ("Timber"), a privately held biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced that they have entered into a definitive merger agreement.… Read More..

Planned Upgrades Expected to Reduce Natural Gas Use, Lower Carbon Intensity of Biofuel, and Decrease Operating Costs by $13 Million Per Year CUPERTINO, CA, Jan. 28, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Aemetis, Inc. (AMTX) (“Aemetis”) announced today that its subsidiary Aemetis Advanced Fuels Keyes, Inc. has received from the California Energy… Read More..

Soligenix is actively enrolling patients in a Phase 3 multinational, double-blind, placebo-controlled clinical trial of SGX942, or dusquetide, for the treatment of oral mucositis in patients with head and neck cancer (HNC) receiving chemoradiation therapy (CRT). Since enrolling its first patent in December 2017 in a controlled rollout of the study… Read More..